Iom Bioworks Raises INR 4 Crore in Seed Round to Advance Microbiome-Based Healthcare
Iom Bioworks aims to personalize health by analyzing and modulating key gut bacteria to support digestion, immunity, metabolism, and overall well-being
You're reading Entrepreneur India, an international franchise of Entrepreneur Media.
Iom Bioworks, a science-driven healthtech startup focused on microbiome-centered wellness, has raised INR 4 crore in Seed Round funding, led by Inflection Point Ventures (IPV). According to a press release by the company, the capital will be used to ramp up marketing efforts, secure intellectual property, build infrastructure, and expand both scientific and commercial teams.
Founded in 2022, Iom Bioworks aims to personalize health by analyzing and modulating key gut bacteria to support digestion, immunity, metabolism, and overall well-being. The company's approach integrates artificial intelligence with microbiome science to offer precise and actionable health recommendations. It claims two granted patents and two more nearing completion, with scientific findings published in peer-reviewed journals.
Within its first year, the company crossed 500 customers and established logistics infrastructure and digital access across India for its microbiome services. "Iom Bioworks envisions a world where a healthy mind and body are achievable through informed choices that nurture the microbiome," said Bipin Pradeep Kumar, co-founder and CEO. "By empowering our inner ecosystem through prebiotics and a food and lifestyle centred around the bacteria, we aim to energize daily life while preserving the joy of living."
Kumar credited the role of their investment partner in supporting the company's growth. "Partnering with IPV has been transformative; their supportive and diligent approach has set us firmly on the path toward this vision," he added.
The startup's scientific leadership includes co-founder and chief of science & technology Dr. Samik Ghosh, who leverages computational biology to develop targeted wellness solutions, and Dr. Hiroaki Kitano, co-founder and chief of research & collaboration, an internationally recognized systems biologist and AI researcher.
Vinay Bansal, founder of IPV, pointed to the growing relevance of gut health in addressing chronic conditions. "Lifestyle diseases have been on the rise due to multiple reasons like poor diet, stress, lack of sleep and are intimately linked to poor gut health and microbial composition," he said. "Iom Bioworks is making this cutting-edge science accessible, personalised and importantly, actionable."
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Axiom-4 mission to space station put on hold
June 20 (UPI) -- NASA will reschedule the Axiom-4 commercial mission to the International Space Station after postponing a launch that had been planned for than Sunday, the space agency said. The agency said it needs to ensure the space station is ready and able to receive added crew members, according to a statement released Thursday. The station's orbital laboratory's Zvezda service module was repaired recently, and NASA is reviewing data to confirm the station's interdependent and interconnected systems are prepared to handle additional people aboard. The planned commercial trip to the space station is to utilize a SpaceX Dragon rocket launched from Kennedy Space Center in Florida. The four-person flight crew members are from different countries, with Indian Space Research Organization astronaut Shubhanshu Shukla to serve as pilot and European Space Agency astronauts Sławosz Uznański-Wiśniewski of Poland and Tibor Kapu of Hungary as mission specialists. The mission is to be commanded by Peggy Whitson, a former NASA astronaut and director of human spaceflight at Axiom Space. "With a culturally diverse crew, we are not only advancing scientific knowledge but also fostering international collaboration," said Whitson in a quote from the Axiom Space website,. "Our previous missions set the stage and with Ax-4, we ascend even higher, bringing more nations to low-Earth orbit and expanding humanity's reach among the stars." According to Axiom Space, the mision is to be "the most research and science-related activities conducted on an Axiom Space mission aboard the International Space Station to date." With the space station in low-Earth orbit, crew members will conduct research under microgravity based in biological, life and material sciences and also undertake Earth observation. The astronauts are being kept in quarantine, and the SpaceX rocket and Crew Dragon capsule are on standby at Kennedy Space Center. Axiom-4 liftoff was originally planned for June 11, but then scrubbed after a leak was found in the Falcon 9 rocket.
Yahoo
an hour ago
- Yahoo
Why India's Budding EV Sector Has Opened Its Doors To China
For decades, China has driven the lion's share of oil demand growth thanks to its remarkable economic boom and large population. However, China is now losing its prominence in global oil markets due to a dramatic slowdown in its economy coupled with the country's ongoing electric vehicle revolution. Last year, nearly half of all new cars sold in China were electric vehicles, including both battery-electric and plug-in hybrid electric vehicles. Indeed, China's rapid adoption of EVs, as well as rapid growth of high-speed rail and natural gas trucks, is displacing traditional fossil fuel demand, with the International Energy Agency (IEA) predicting that China's oil demand will peak as early as 2027. Ironically, the country that is taking over China's mantle in world oil markets is also aspiring to follow in its EV footsteps: India. Unlike China, India's EV sector is still at its infancy, with electric vehicles accounting for just 2.5% of all cars sold in the country in 2024. However, India has big EV ambitions, with the Indian government having set a target for EVs to make up 30% of total passenger vehicle sales by 2030. To accomplish this, India's EV sector is forging close ties with Chinese EV manufacturers at a time when Washington has been keeping Chinese EV giants at bay. India is relying on Chinese EV tech to bridge the gap until the domestic sector is ready to compete on the global stage. Industry analysts note that without access to Chinese technologies—including batteries, drivetrain components, and EV software—India would likely face slower product rollouts, limited model variety, and higher costs during its growth phase. This marks a clear pivot from just a few years ago, when India restricted the operations of firms like BYD and banned popular Chinese apps such as TikTok and Shein after deadly clashes at the New Delhi appears to be taking a more calculated stance. In March, the government reduced tariffs on over 35 EV components, many of which are imported from China, making it easier for automakers to source critical parts. A few weeks later, India's Ministry of Heavy Industries unveiled a new EV policy slashing import duties on fully built EVs from 110% to 15%, provided manufacturers invest and set up local production. This dual-pronged approach aims to attract international players while building out domestic supply chains. Experts view these shifts as pragmatic. Leading Indian EV makers—such as Tata Motors, Ola Electric, and Mahindra & Mahindra—continue to depend on Chinese vendors for components like battery cells, power control units, and electric motors, even though assembly is carried out in India. 'The aim is to build a resilient domestic ecosystem, not to isolate it, unlike the more aggressive decoupling seen in the U.S. with China,' said Shubham Munde, senior analyst at intelligence firm Market Research Future. Yet this growing alignment between Indian and Chinese EV sectors is creating both opportunity and competition. MG Motor—a joint venture between India's JSW Group and China's state-owned automaker SAIC—has managed to double its market share over the past year, putting pressure on homegrown giants like Tata Motors. Its model, the MG Windsor, is now India's top-selling electric car, highlighting how joint ventures are gaining traction. At the same time, India's EV landscape remains deeply fragmented. According to Bernstein Research, just four legacy automakers dominate 80% of the electric mobility market, leaving over 150 EV startups struggling to establish a foothold in an increasingly competitive space. Government policy appears to be playing an outsized role in the EV trajectories of different countries. In its 2025 Electric Vehicles Outlook, Bloomberg New Energy Finance (BNEF) cut both its near-term and long-term passenger EV adoption outlook in the United States for the first time ever, citing key policy changes including rollback of national fuel-economy targets as well as the removal of supportive elements of the Inflation Reduction Act (IRA) by the Trump administration. In contrast, S&P Global Mobility has forecast strong growth for India's nascent EV sector, projecting that production of battery-electric passenger vehicles will increase by 140% year-over-year in 2025 to roughly 301,400 units. That would represent about 6% of the estimated 5.16 million passenger vehicles expected to be built in India that year. Still, the road to India's 2030 goal may be steep. According to S&P, India would need to boost EV adoption by approximately 380 basis points annually to reach 30% market share—nearly double the current growth rate of around 200 basis points per year since 2021. Compounding the challenge is the lack of a unified long-term roadmap and the pending expiration of several state-level EV incentive programs. By Alex Kimani for More Top Reads From this article on Fehler beim Abrufen der Daten Melden Sie sich an, um Ihr Portfolio aufzurufen. Fehler beim Abrufen der Daten Fehler beim Abrufen der Daten Fehler beim Abrufen der Daten Fehler beim Abrufen der Daten
Yahoo
4 hours ago
- Yahoo
PharmaSens and SiBionics to develop wearable insulin patch pump
Swiss company PharmaSens and SiBionics have entered a development partnership for niia signature, an all-in-one wearable that integrates the delivery of insulin with continuous glucose monitoring (CGM) into a compact pump. Through this device, the parties anticipate simplifying the management of diabetes for individuals who utilise insulin, aiming to minimise the daily therapy load. The wearable will leverage PharmaSens' patented platform technologies along with the biosensor capabilities of SiBionics. Both companies will offer their engineering and development know-how to bring this patch pump to the market. PharmaSens CEO Marcel Both said: 'This partnership marks a significant milestone toward realising our vision of a fully integrated, discreet, and intuitive insulin-therapy system. 'SiBionics' proven expertise in sensor technology is a perfect complement to our platform.' PharmaSens is currently developing a portfolio of three insulin patch pumps, including niia signature, designed to cater to a broad range of user needs. The range begins with the niia essential, a basal-bolus insulin pump that prioritises ease of use by minimising complexity. The niia advanced provides additional options and can be controlled through a smartphone, also allowing connection to an external CGM. PharmaSens highlights that its devices consist of one reusable part, comprising the pump and CGM electronics with a two-year lifespan, and one disposable part, which includes a 3ml insulin reservoir to extend wear time and reduce insulin waste. The company is focused on simplifying diabetes management and expanding access to insulin pump therapy. Founded in 2015, CGM technology provider SiBionics brings to the partnership its core expertise in medical device research and development, with offices in China and the US. Last year, PharmaSens submitted an application to the US Food and Drug Administration (FDA) for approval of its niia essential insulin patch pump system. "PharmaSens and SiBionics to develop wearable insulin patch pump" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
